Table 3.

Treatment-emergent adverse reactions and laboratory abnormalities in 146 patients with indolent lymphoma treated with idelalisib, 150 mg twice daily

Any graden (%)Grade 3n (%)
Adverse reactions ≥10%
 Diarrheaa68 (47)20 (14)
 Fatigue44 (30)2 (1)
 Nausea42 (29)2 (1)
 Cough42 (29)1 (1)
 Pyrexia41 (28)3 (2)
 Abdominal paina38 (26)3 (2)
 Pneumoniaa37 (25)23 (16)
 Rasha31 (21)4 (3)
 Dyspnea25 (17)6 (4)
 Decreased appetite24 (16)1 (1)
 Vomiting22 (15)2 (1)
 Upper respiratory tract infection18 (12)0
 Night sweats18 (12)0
 Asthenia17 (12)3 (2)
 Insomnia17 (12)0
 Headache16 (11)1 (1)
 Peripheral edema15 (10)3 (2)
Laboratory abnormalities ≥25%
 Neutrophils decreased78 (53)36 (25)
 ALT increased73 (50)27 (18)
 AST increased60 (41)18 (12)
 Hemoglobin decreased41 (28)3 (2)
 Platelets decreased38 (26)9 (6)
  • aGrouped terms. See Supplementary Table S1 for further information.